849353-44-2

Upstream product

• 15777-70-5 4-hydroxy-3-methylbenzonitrile 
• 13061-96-6 dihydroxy-methyl-borane 
• 1689-89-0 nitroxynil 
• 6933-10-4 amino-5-bromo-2-toluene 
• 41963-20-6 4-bromo-3-methylbenzonirtile 
• 854627-73-9 4-bromo-3-methyl-5-nitrobenzonitrile 

Downstream Products

• 1093397-19-3 4-(5-cyano-7-methyl-1,3-benzoxazol-2-yl)-N-({1-[4-(trifluoromethyl)phenyl]piperidin-4-yl}methyl)benzamide 
• 1292821-35-2 C₃₀H₂₇F₃N₄O₂ 
• 1093565-24-2 C₁₆H₁₀N₂O₃ 
• 1292821-26-1 C₂₇H₂₁F₃N₄O₂ 
• 942215-54-5 3-amino-4-hydroxy-5-methylbenzonitrile 
• 1093397-18-2 methyl 4-(5-cyano-7-methyl-1,3-benzoxazol-2-yl)benzoate 
• 1093397-20-6 lithium 4-(5-cyano-7-methyl-1,3-benzoxazol-2-yl)benzoate 
• 850335-09-0 methyl 4-hydroxy-3-methyl-5-nitrobenzoate 

Relevant academic research and scientific papers

2-(4-Carbonylphenyl)benzoxazole inhibitors of CETP: Scaffold design and advancement in HDLc-raising efficacy

The development of 2-phenylbenzoxazoles as inhibitors of cholesteryl ester transfer protein (CETP) is described. Initial efforts aimed at engineering replacements for the aniline substructures in the benchmark molecule. Reversing the connectivity of the central aniline lead to a new class of 2-(4-carbonylphenyl)benzoxazoles. Structure-activity studies at the C-7 and terminal pyridine ring allowed for the optimization of potency and HDLc-raising efficacy in this new class of inhibitors. These efforts lead to the discovery of benzoxazole 11v, which raised HDLc by 24 mg/dl in our transgenic mouse PD model.

CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES

Compounds having the structure of Formula I1 including pharmaceutically acceptable salts of the compounds, are potent CETP (cholesterol ester transfer protein) inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis Atherosclerosis and its clinical consequences, coronary heart disease (CHD), stroke and penpheral vascular disease, represent a truly enormous burden to the health care systems ofthe industrialized world In formula I, A-B is an arylamide moiety

1,1,1-TRIFLUORO-4-PHENYL-4-METHYL-2-(1H-PYRROLO

Compounds of Formula (IA), IB), IC), and (ID) wherein R1, R2, R3, R4, R5, and R6 are as respectively defined herein for Formula (IA), (IB), (IC), and (ID), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.